These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Targeted Bifunctional Proteins and Hybrid Nanoconstructs for Cancer Diagnostics and Therapies]. Deyev SM; Lebedenko EN Mol Biol (Mosk); 2017; 51(6):907-926. PubMed ID: 29271956 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic antibodies and antibody fusion proteins. Rohrbach P; Broders O; Toleikis L; Dübel S Biotechnol Genet Eng Rev; 2003; 20():137-63. PubMed ID: 14997850 [No Abstract] [Full Text] [Related]
6. Plant-Produced Monoclonal Antibody as Immunotherapy for Cancer. Nessa MU; Rahman MA; Kabir Y Biomed Res Int; 2020; 2020():3038564. PubMed ID: 32908881 [TBL] [Abstract][Full Text] [Related]
7. Engineering mouse monoclonal antibodies for cancer immunotherapy. Orlandi R Year Immunol; 1993; 7():69-73. PubMed ID: 8372514 [No Abstract] [Full Text] [Related]
8. Human monoclonal antibodies for discovery, therapy, and vaccine acceleration. Andreano E; Seubert A; Rappuoli R Curr Opin Immunol; 2019 Aug; 59():130-134. PubMed ID: 31450054 [TBL] [Abstract][Full Text] [Related]
9. Development of a neutralizing mouse-pig chimeric antibody with therapeutic potential against Haemophilus parasuis in Pichia pastoris. Chai Z; Fu F; Jiang F; Tian H; Wang Z; Zheng N; Zhang X; Wang X; Li X FEMS Microbiol Lett; 2014 May; 354(2):85-91. PubMed ID: 24698098 [TBL] [Abstract][Full Text] [Related]
10. Letter from the editor. Reichert JM MAbs; 2009; 1(3):189. PubMed ID: 20065629 [No Abstract] [Full Text] [Related]
11. Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Li X; Mao C; Ma S; Wang X; Sun Z; Yi Y; Guo M; Shen X; Sun L; Bi S Biochem Biophys Res Commun; 2009 Dec; 390(4):1126-8. PubMed ID: 19799860 [TBL] [Abstract][Full Text] [Related]
12. [Monoclonal antibodies in diseases of viral origin]. Aguilar Setién A; Kretschmer R Salud Publica Mex; 1985; 27(3):251-9. PubMed ID: 2996158 [No Abstract] [Full Text] [Related]
13. Therapeutic antibodies: magic bullets hit the target. Gura T Nature; 2002 Jun; 417(6889):584-6. PubMed ID: 12050630 [No Abstract] [Full Text] [Related]
15. Construction of a hepatitis B virus neutralizing chimeric monoclonal antibody recognizing escape mutants of the viral surface antigen (HBsAg). Golsaz-Shirazi F; Amiri MM; Farid S; Bahadori M; Bohne F; Altstetter S; Wolff L; Kazemi T; Khoshnoodi J; Hojjat-Farsangi M; Chudy M; Jeddi-Tehrani M; Protzer U; Shokri F Antiviral Res; 2017 Aug; 144():153-163. PubMed ID: 28641998 [TBL] [Abstract][Full Text] [Related]
16. Development of humanized antibodies as cancer therapeutics. Qu Z; Griffiths GL; Wegener WA; Chang CH; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM Methods; 2005 May; 36(1):84-95. PubMed ID: 15848077 [TBL] [Abstract][Full Text] [Related]
17. Development of antibodies and chimeric molecules for cancer immunotherapy. Waldmann TA; Morris JC Adv Immunol; 2006; 90():83-131. PubMed ID: 16730262 [TBL] [Abstract][Full Text] [Related]
18. Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases. Talotta R; Rucci F; Canti G; Scaglione F Immunotherapy; 2019 Feb; 11(3):241-254. PubMed ID: 30730275 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic applications of monoclonal antibodies. Berger M; Shankar V; Vafai A Am J Med Sci; 2002 Jul; 324(1):14-30. PubMed ID: 12120821 [TBL] [Abstract][Full Text] [Related]
20. Construction and characterization of a new chimeric antibody against HER2. Amiri MM; Jeddi-Tehrani M; Kazemi T; Bahadori M; Maddah M; Hojjat-Farsangi M; Khoshnoodi J; Rabbani H; Shokri F Immunotherapy; 2013 Jul; 5(7):703-15. PubMed ID: 23829622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]